If a management change such as alendronate reinitiation would be considered when BMD T-score drops below -2.5 , the model shows that women with total hip BMD greater than -1.9 T-scores at the time of alendronate discontinuation have less than a 20 % probability that at follow-up , monitoring BMD will be below the threshold within 5 years .